Lab21 Ltd to Provide AdnaGen’s System for CTCs in the United Kingdom and Ireland
OVIT Announces Collaboration with MDACC on AdnaGen CTC Assay Development
AndaGen AG Completes Successful Financial Restructuring
CTRC and OncoVista Announce Initiation of Collaboration on Clinical Development of OVI-117
AdnaGen AG and OncoVista Innovative Therapies Inc., Announce the Issuance in the US of a Key Patent
Sysmex to Distribute AdnaGen Kits in Europe
OncoVista Innovative Therapies, Inc. to Present at Rodman & Renshaw Healthcare Conference
OncoVista Announces Initiation of Research Coverage by Status Equity Research
OncoVista Innovative Therapies to Begin Enrolling Patients in Cordycepin Phase I/II Trial
OncoVista, Inc. Increases Ownership of AdnaGen AG
OncoVista Innovative Therapies' Information to be Available Through S&P Market Access Program
OncoVista Innovative Therapies, Inc. Announces Submission of Request for pre-IDE Meeting
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer
OncoVista Innovative Therapies, Inc. is Trading on the Frankfurt Stock Exchange
OncoVista Innovative Therapies, Inc. Changes Name From Aviation Upgrade Technologies
OncoVista Innovative Therapies, Inc. Appoint J. Michael Edwards New Chief Financial Officer
OncoVista Increases its Share in AdnaGen AG
OncoVista Licenses Phase II Clinical-Stage Drug From OSI Pharmaceuticals
|
